HYDERABAD: Dr Reddy’s Laboratories on Monday said it has expanded its strategic partnership with French biopharma giant ...

A study by former Junior Associate Professor Kazuo Takayama, currently a professor of the Institute of Science Tokyo, ...

The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

Those recommendations on Wednesday were: — People 50 to 59 should be able to get vaccinated against respiratory syncytial ...

Leveraging structural biology-based design, we engineered the RSV pre-F protein and validated the potential ... 1:1620, and 1:4860. A virus stock with a previously determined titer, stored at -80°C, ...

Dr. Stephen Blatt, Medical Director for Infectious Diseases at TriHealth, highlighted the symptoms associated with the virus ... mentioned that while flu and RSV cases are declining, complications ...

The RSV immunization campaign ended on April 1, 2025. Respiratory syncytial virus (RSV) immunization for babies consists of the administration of a preventive treatment to eligible children. The ...

Intranasal influenza virus-vectored vaccine offers protection against clade 2.3.4.4b H5N1 infection in small animal models. Nature Communications , 2025; 16 (1) DOI: 10.1038/s41467-025-58504-z ...

Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key ...